We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01314391
Recruitment Status : Completed
First Posted : March 14, 2011
Last Update Posted : May 18, 2016
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group

March 11, 2011
March 14, 2011
May 18, 2016
August 2011
May 2016   (Final data collection date for primary outcome measure)
Higher incidence of ESRD in non-syndromic WT patients with germline WT1 mutations than WT patients without WT1 mutations
Same as current
Complete list of historical versions of study NCT01314391 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor
Pilot Case-Control Study of WT1 Mutations in Wilms Tumor Patients Who Develop ESRD

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in blood and tumor tissue samples from patients with Wilms tumor.


  • To determine whether Wilms Tumor (WT) patients without WT1-associated congenital anomalies or syndromes, but with end-stage renal disease (ESRD) unrelated to progressive bilateral tumors, carry germline WT1 mutations.
  • To determine whether non-syndromic WT1 germline mutation carriers have a substantially higher incidence of ESRD than do WT patients who do not harbor WT1 mutations.

OUTLINE: Archived blood and tumor tissue specimens (or DNA isolated from these samples) are analyzed for WT1 mutations by gene sequencing and PCR.

Observational Model: Case Control
Time Perspective: Retrospective
Not Provided
Retention:   Samples With DNA
Blood and Tumor tissue
Non-Probability Sample
Diagnosis of Wilms Tumor
  • Kidney Cancer
  • Renal Failure
  • Genetic: mutation analysis
  • Genetic: polymerase chain reaction
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
May 2016   (Final data collection date for primary outcome measure)


  • Diagnosis of Wilms Tumor (WT)
  • Patients who participated in the NWTS-5 protocol

    • Non-syndromic patients who developed end-stage renal disease (ESRD) during 5-10 years for reasons other than progressive bilateral WT
    • Matched control patients who had not developed ESRD by the time (since WT onset) of ESRD diagnosis
  • Blood and tumor tissue samples available


  • Not specified


  • Not specified
Sexes Eligible for Study: All
up to 15 Years   (Child)
Contact information is only displayed when the study is recruiting subjects
Not Provided
COG-AREN11B1 ( Other Identifier: Children's Oncology Group )
NCI-2011-02850 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
AREN11B1 ( Other Identifier: Children's Oncology Group )
Not Provided
Not Provided
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Vicki Huff, PhD M.D. Anderson Cancer Center
Children's Oncology Group
May 2016